SEC Form 4 · accession 0001127602-19-006101

BIOGEN INC. · BIIB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Feb 12, 2019

Accepted (ET)

Feb 14, 2019 · 6:33 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875045

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Feb 12, 2019	M	6,899	$0.00	A	16,267	D
Common Stock	Feb 12, 2019	F	2,622	$319.43	D	13,645	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Unit^F1	$0.00	Feb 12, 2019	M	6,899	D	—	Feb 12, 2021	Common Stock	6,899	29,421	D
Restricted Stock Unit^F2,F1	$0.00	Feb 12, 2019	J	5,205	D	—	Feb 12, 2021	Common Stock	5,205	24,216	D
Restricted Stock Unit^F1	$0.00	Feb 12, 2019	A	37,570	A	—	Feb 12, 2022	Common Stock	37,570	37,570	D

F1The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F2This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.